Applied BioCode Corporation (6598.TW)

TWD 18.9

(-0.79%)

EBITDA Summary of Applied BioCode Corporation

Applied BioCode Corporation's latest annual EBITDA in 2023 was -98.59 Million TWD , up 1.11% from previous year.
Applied BioCode Corporation's latest quarterly EBITDA in 2024 Q2 was -40.47 Million TWD , up 27.45% from previous quarter.
Applied BioCode Corporation reported an annual EBITDA of -125.41 Million TWD in 2022, down -12.63% from previous year.
Applied BioCode Corporation reported an annual EBITDA of -111.34 Million TWD in 2021, down -100.39% from previous year.
Applied BioCode Corporation reported a quarterly EBITDA of -53.78 Million TWD for 2024 Q1, down -692.2% from previous quarter.
Applied BioCode Corporation reported a quarterly EBITDA of 976 Thousand TWD for 2023 Q4, up 103.62% from previous quarter.

Annual EBITDA Chart of Applied BioCode Corporation (2023 - 2013)

Historical Annual EBITDA of Applied BioCode Corporation (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	-98.59 Million TWD	1.11%
2022	-125.41 Million TWD	-12.63%
2021	-111.34 Million TWD	-100.39%
2020	-55.56 Million TWD	76.91%
2019	-240.65 Million TWD	4.12%
2018	-250.99 Million TWD	-0.08%
2017	-250.37 Million TWD	-36.93%
2016	-180.61 Million TWD	13.51%
2015	-211.76 Million TWD	-36.03%
2014	-155.67 Million TWD	-99.23%
2013	-78.14 Million TWD	0.0%

Year	EBITDA	EBITDA Growth
2024 Q2	-40.47 Million TWD	27.45%
2024 Q1	-53.78 Million TWD	-692.2%
2023 Q4	976 Thousand TWD	103.62%
2023 FY	- TWD	1.11%
2023 Q1	-34.43 Million TWD	-77.93%
2023 Q2	-44.91 Million TWD	-30.46%
2023 Q3	-26.93 Million TWD	40.04%
2022 FY	- TWD	-12.63%
2022 Q1	-60 Million TWD	-410.27%
2022 Q4	-19.35 Million TWD	33.08%
2022 Q3	-28.91 Million TWD	-68.69%
2022 Q2	-17.14 Million TWD	71.44%
2021 Q4	-11.76 Million TWD	75.18%
2021 Q2	-41.46 Million TWD	-286.02%
2021 Q1	-10.74 Million TWD	-118.1%
2021 FY	- TWD	-100.39%
2021 Q3	-47.38 Million TWD	-14.28%
2020 FY	- TWD	76.91%
2020 Q4	59.34 Million TWD	683.58%
2020 Q3	-10.16 Million TWD	85.71%
2020 Q2	-71.16 Million TWD	-111.96%
2020 Q1	-33.57 Million TWD	26.39%
2019 Q3	-57.79 Million TWD	14.73%
2019 FY	- TWD	4.12%
2019 Q1	-69.46 Million TWD	-10.69%
2019 Q2	-67.78 Million TWD	2.42%
2019 Q4	-45.61 Million TWD	21.09%
2018 Q2	-57.48 Million TWD	0.0%
2018 FY	- TWD	-0.08%
2018 Q4	-62.75 Million TWD	14.46%
2018 Q3	-73.36 Million TWD	-27.61%
2018 Q1	-57.48 Million TWD	-0.37%
2017 Q3	-57.27 Million TWD	16.04%
2017 Q2	-68.21 Million TWD	0.0%
2017 Q4	-57.27 Million TWD	0.0%
2017 Q1	-68.21 Million TWD	0.0%
2017 FY	- TWD	-36.93%
2016 Q4	- TWD	0.0%
2016 Q2	-45.16 Million TWD	0.0%
2016 FY	- TWD	13.51%
2015 FY	- TWD	-36.03%
2015 Q4	- TWD	0.0%
2014 FY	- TWD	-99.23%
2013 FY	- TWD	0.0%

Peer EBITDA Comparison of Applied BioCode Corporation

Name	EBITDA	EBITDA Difference
Excelsior Medical Co., Ltd.	968.55 Million TWD	110.179%
Apex Medical Corp.	318.12 Million TWD	130.991%
OK Biotech Co., Ltd.	87.24 Million TWD	213.006%